| Pharmaceutical active ingredients: |
| AvobenzoneHydroquinoneOctinoxate |
| Available forms, composition and doses of Lustra-AF: |
| Cream; Topical; Avobenzone 3%; Hydroquinone 4%; Octinoxate 7.5% |
| Lustra-AF medical category: |
| Human:Depigmenting agents |
| Indications and usages, anatomical therapeutic chemical and diseases classification codes: |
| D11AX11 - Hydroquinone |
| Pharmaceutical companies: manufacturers, researchers, developers, local distributors and suppliers: |
| Taro Pharmaceutical IndustriesMedicis Pharmaceutical Corporation |
| Trade name |
Active ingredients |
Pharmaceutical company |
|
Levetiracetam | Levetiracetam | Taro Pharmaceutical Industries |
| Lidocaine | Lidocaine | Taro Pharmaceutical Industries |
| Loratadine | Loratadine | Taro Pharmaceutical Industries |
| Lozapine | Clozapine | Taro Pharmaceutical Industries |
| Lustra | Hydroquinone | Taro Pharmaceutical Industries; Medicis Pharmaceutical Corporation |
| Lyderm | Fluocinonide | Taro Pharmaceutical Industries |
| Medixel | Paclitaxel | Taro Pharmaceutical Industries |
| Meprobamate | Meprobamate | Taro Pharmaceutical Industries |
| Mercaptizol | Methimazole | Taro Pharmaceutical Industries |
| Meroken New | Polyethylene Glycol; Potassium Chloride; Sodium Bicarbonate; Sodium Chloride | Taro Pharmaceutical Industries |